Diagnostic therapeutic method

Abstract

A pharmaceutical preparation containing magnetic vesicular particles is disclosed, wherein the magnetic vesicular particles each include magnetic microparticles within a lipid membrane, an organic compound having at least two groups selected from the group consisting of a hydroxyl group, a carboxyl group, a carbamoyl group, an amino group, a mercapto group, a sulfo group, a dithio group, a thiocarboxyl group and a dithiocarboxyl group is bonded to the magnetic microparticle, and the magnetic vesicular particles satisfy the following equation: 0.05≦ R /( r ×100)≦1.5 wherein R represents an average grain size of the magnetic vesicular particles and r represents an average particle size of magnetic microparticles included in the magnetic vesicular particles.

1 . A diagnostic test method for an examinee using ultrasonic imaging, nuclear magnetic resonance imaging or radiographic imaging, comprising:
 injecting into a vein of an examinee a preparation containing magnetic vesicular particles, wherein the magnetic vesicular particles, each includes at least one magnetic microparticle within a lipid membrane, an organic compound having at least two groups selected from the group consisting of a carboxyl group, a carbamoyl group, an amino group, a mercapto group, a sulfo group, and a dithio group is bonded to the magnetic microparticles, and the magnetic vesicular particles satisfy the following equation:
   0.05≦ R /( r× 100)≦1.5 
   
     wherein R represents an average grain size of the magnetic vesicular particles and r represents an average particle size of magnetic microparticles included in the magnetic vesicular particles, wherein the organic compound is a compound selected from the group consisting of phthalic acid, isophthalic acid, terephthalic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, fumaric acid, maleic acid, 2-mercaptoamine, 6-aminehexanethiol, 2-mercaptopropionic acid, asparagic acid, glutamine, malic acid, oxaloacetic acid, 2-ketoglutaric acid, serine, threonine, cysteine, cysteic acid, cystine, N-acetylcysteine, cysteine ethyl ester and dithiothreitol; and
 scanning the examinee, within not less than 1 minute and not more than 48 hours after injecting, using an ultrasonic imaging diagnosis apparatus, a nuclear magnetic resonance imaging diagnosis apparatus or a radiographic imaging diagnosis apparatus. 
 
   
   
       2 . The method of  claim 1 , wherein, within not less than 0.5 minute and not more than 36 hours after injecting the preparation into a region near a tumorous tissue of an examinee, scanning is conducted. 
   
   
       3 . The method of  claim 1 , wherein at least one material selected from the group consisting of a physiologically functional material, an additively stabilizing material, a medicinally active material, a medicinally active chelating material, an antitumor-active material, an immunopotentiating material, a cell fusion material, and a gene transfer mediating material is bonded directly or through a linking material to an outermost layer of the lipid membrane of the magnetic vesicular particle. 
   
   
       4 . A method for the thermotherapy comprising:
 injecting into a vein of a patient a preparation containing magnetic vesicular particles, wherein the magnetic vesicular particles, each includes at least one magnetic microparticle within a lipid membrane, an organic compound having at least two groups selected from the group consisting of a carboxyl group, a carbamoyl group, an amino group, a mercapto group, a sulfo group, and a dithio group is bonded to the magnetic microparticles, and the magnetic vesicular particles satisfy the following equation:
   0.05≦ R /( r× 100)≦1.5 
   wherein R represents an average grain size of the magnetic vesicular particles and r represents an average particle size of magnetic microparticles included in the magnetic vesicular particles, wherein the organic compound is a compound selected from the group consisting of phthalic acid, isophthalic acid, terephthalic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, fumaric acid, maleic acid, 2-mercaptoamine, 6-aminehexanethiol, 2-mercaptopropionic acid, asparagic acid, glutamine, malic acid, oxaloacetic acid, 2-ketoglutaric acid, serine, threonine, cysteine, cysteic acid, cystine, N-acetylcysteine, cysteine ethyl ester and dithiothreitol;   scanning the examinee, within not less than 1 minute and not more than 48 hours after injecting, using an ultrasonic imaging diagnosis apparatus, a nuclear magnetic resonance imaging diagnosis apparatus or a radiographic imaging diagnosis apparatus; and   exposing the patient to energy after injecting so as to conduct thermotherapy.   
   
   
       5 . The method of  claim 4 , wherein the energy raises a temperature of a tumorous tissue close to the magnetic grains. 
   
   
       6 . The method of  claim 5 , wherein the energy is from an alternating magnetic field or an ultrasonic. 
   
   
       7 . The method of  claim 5 , wherein the energy is from an alternating magnetic field at a frequency of 25 to 500 Hz. 
   
   
       8 . The method of  claim 6 , wherein when the patient is exposed to the alternating magnetic field or the ultrasonic within 1 minute to 48 hours after the preparation is injected into the vein of the patient, the preparation raises a temperature of a tumorous tissue close to the magnetic grains. 
   
   
       9 . The method of  claim 6 , wherein when the patient is exposed to the alternating magnetic field or the ultrasonic within 0.5 min. to 36 hours after the preparation is injected into a region near a tumorous tissue of the patient, the preparation raises a temperature of the tumorous tissue close to the magnetic vesicular particles.